Patients with multiple myeloma may not be receiving optimal therapy for bone disease.

Accredited CME from Imedex

Robert Z Orlowski, MD, PhD, outlines the key take-home messages from the session on plasma cell disorders by first outlining the most current evidence-based data for initial, maintenance, and refractory/relapsed therapy.
David P Steensma, MD outlines the key take-home messages from the leukemia, benign hematology, and myeloid disorders sessions by providing an overview of new and emerging evidence-based data for CLL, non-malignant hematology, CML, ALL, MDS, and MPN.
John P Leonard, MD, outlines the key take-home messages from the lymphoma session by providing an overview of evidence-based data pertinent to practicing clinicians in the therapeutic area of lymphoma.


Clinicians are now trying to treat multiple myeloma similar to leukemia, according to George Somlo, MD, who discussed treatment regimens at the 2016 NCCN Annual Congress on Hematologic Malignancies.
Since 2015, the US Food and Drug Administration has approved 4 new therapies for the treatment of multiple myeloma: panobinostat, daratumumab, ixazomib, and elotuzumab.
Autologous stem cell transplantation is still the preferred treatment of choice for patients under the age of 65 years with newly diagnosed multiple myeloma.


Patients with multiple myeloma may not be receiving optimal therapy for bone disease.
Patients with newly diagnosed multiple myeloma who are unable to undergo stem cell transplantation live significantly longer and with delayed disease progression when given a continuous novel treatment regimen.
Specific age, health status, race, and socioeconomic factors may be associated with a lack of systemic treatment for multiple myeloma.
A combination regimen may be effective in patients with relapsed or refractory multiple myeloma and moderate to severe renal impairment, especially in those with advanced disease requiring hemodialysis.


According to a recent study, maintenance therapy with which agent prolongs time to remission after autologous stem cell transplantation in multiple myeloma?
According to recent research presented at ASCO, adding which targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone is a safe and efficacious alternative to ASCT for patients with multiple myeloma?

Research in Review

Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma.
Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median PFS by 14 months compared with patients who receive chemotherapy alone.
Single agent daratumumab may serve as a more cost-effective treatment strategy than pomalidomide for patients with refractory multiple myeloma.
A triple-combination treatment strategy is the most effective therapy for patients with relapsed or refractory multiple myeloma.
Subscribe to Hematologic Malignancies